國立虎尾科技大學 |

Intracellular Delivery III = Market Entry Barriers of Nanomedicines /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Intracellular Delivery III/ edited by Aleš Prokop, Volkmar Weissig.
其他題名:	Market Entry Barriers of Nanomedicines /
其他作者:	Prokop, Aleš.
面頁冊數:	XIII, 453 p. 81 illus., 65 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Medicine. -
電子資源:	https://doi.org/10.1007/978-3-319-43525-1
ISBN:	9783319435251

Intracellular Delivery III = Market Entry Barriers of Nanomedicines /
Intracellular Delivery IIIMarket Entry Barriers of Nanomedicines /[electronic resource] :edited by Aleš Prokop, Volkmar Weissig. - 1st ed. 2016. - XIII, 453 p. 81 illus., 65 illus. in color.online resource. - Fundamental Biomedical Technologies,1559-7083. - Fundamental Biomedical Technologies,.

1 Overview of present problems facing commercialization of nanomedicines, Aleš Prokop and Volkmar Weissig -- 2 Precision medicine and site-specific drug delivery, Karel Petrák -- 3 Extracellular matrix degrading enzymes for nanocarrier-based anticancer therapy, Pablo Scodeller -- 4 Nanocarrier-based anticancer therapies with the focus on strategies for targeting the tumor microenvironment, Francisca Leonard and Biana Godin -- 5 New approach to minimize the MPS/RES uptake resulting a reduce toxic side effects of nanodrugs, Li Liu and Chien Ho -- 6 Authentic vascular and stromal structure in animal disease model for nanomedicine, Hiroshi Nishihara and Mitsunobu R Kano -- 7 Ligand-targeted nanocarriers with respect to their translation into the clinic, in particular in comparison with non-targeted nano-medicines, Roy Van der Meel, Laurens J.C. Vehmeijer, Robbert Jan Kok, Gert Storm, Ethlinn V.B. van Gaaland Gert Storm -- 8 Anti-angiogenic therapy by targeting the tumor vasculature with liposomes, Yu Sakurai and Hideyoshi Harashima -- 9 Accessing mitochondrial targets using nanocargos, Ru Wen, Afoma C. Umeano and Shanta Dhar -- 10 Redox-responsive nano-delivery systems for cancer therapy, Amit Singh, Thanh-Huyen Tran and Mansoor M. Amiji -- 11 Nano-emulsions for drug delivery and biomedical imaging, Nicolas Anton, François Hallouard, Mohammed F. Attia and Thierry F. Vandamme -- 12 The tumor microenvironment in nanoparticle delivery and the role of Imaging to navigate roadblocks and pathways, Dmitri Artemov and Zaver M Bhujwalla -- 13 Microscopic mass spectrometry for the precise design of drug delivery systems, Yasuhiro Matsumura and Masahiro Yasunaga -- 14 Pharmacokinetics and pharmacodynamics of nano-drug delivery systems, David Stepensky -- 15 Intracellular drug delivery in PBPK modelling though active and passive transport processes, Lars Kuepfer, Christoph Niederalt, Thomas Wendl, Jan-Frederil Schlender, Michael Block, Thomas Eissing, Donato Teutonic -- 16 Exploiting nanocarriers for combination cancer therapy, Yi Wen Kong, Erik C. Dreaden, Paula T. Hammond and Michael B. Yaffe -- 17 Commercialization of nanotechnology for medical applications, David W. Hobson -- Index.

A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new “drugs” will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently “nanomaterials” have been said to “show promise” but none of these promises have so far been “reduced” to human clinical practice. The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies). Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies. Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug–carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile.

ISBN: 9783319435251

Standard No.: 10.1007/978-3-319-43525-1doiSubjects--Topical Terms:

644133
Medicine.

LC Class. No.: R-RZ

Dewey Class. No.: 610

Intracellular Delivery III = Market Entry Barriers of Nanomedicines /
LDR:05567nam a22004095i 4500 001 979804
003 DE-He213
005 20200704025734.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319435251 $9 978-3-319-43525-1
024 7 $a 10.1007/978-3-319-43525-1 $2 doi
035 $a 978-3-319-43525-1
050 4 $a R-RZ
072 7 $a MBGR $2 bicssc
072 7 $a MED000000 $2 bisacsh
072 7 $a MBGR $2 thema
082 0 4 $a 610 $2 23
245 1 0 $a Intracellular Delivery III $h [electronic resource] : $b Market Entry Barriers of Nanomedicines / $c edited by Aleš Prokop, Volkmar Weissig.
250 $a 1st ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a XIII, 453 p. 81 illus., 65 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Fundamental Biomedical Technologies, $x 1559-7083
505 0 $a 1 Overview of present problems facing commercialization of nanomedicines, Aleš Prokop and Volkmar Weissig -- 2 Precision medicine and site-specific drug delivery, Karel Petrák -- 3 Extracellular matrix degrading enzymes for nanocarrier-based anticancer therapy, Pablo Scodeller -- 4 Nanocarrier-based anticancer therapies with the focus on strategies for targeting the tumor microenvironment, Francisca Leonard and Biana Godin -- 5 New approach to minimize the MPS/RES uptake resulting a reduce toxic side effects of nanodrugs, Li Liu and Chien Ho -- 6 Authentic vascular and stromal structure in animal disease model for nanomedicine, Hiroshi Nishihara and Mitsunobu R Kano -- 7 Ligand-targeted nanocarriers with respect to their translation into the clinic, in particular in comparison with non-targeted nano-medicines, Roy Van der Meel, Laurens J.C. Vehmeijer, Robbert Jan Kok, Gert Storm, Ethlinn V.B. van Gaaland Gert Storm -- 8 Anti-angiogenic therapy by targeting the tumor vasculature with liposomes, Yu Sakurai and Hideyoshi Harashima -- 9 Accessing mitochondrial targets using nanocargos, Ru Wen, Afoma C. Umeano and Shanta Dhar -- 10 Redox-responsive nano-delivery systems for cancer therapy, Amit Singh, Thanh-Huyen Tran and Mansoor M. Amiji -- 11 Nano-emulsions for drug delivery and biomedical imaging, Nicolas Anton, François Hallouard, Mohammed F. Attia and Thierry F. Vandamme -- 12 The tumor microenvironment in nanoparticle delivery and the role of Imaging to navigate roadblocks and pathways, Dmitri Artemov and Zaver M Bhujwalla -- 13 Microscopic mass spectrometry for the precise design of drug delivery systems, Yasuhiro Matsumura and Masahiro Yasunaga -- 14 Pharmacokinetics and pharmacodynamics of nano-drug delivery systems, David Stepensky -- 15 Intracellular drug delivery in PBPK modelling though active and passive transport processes, Lars Kuepfer, Christoph Niederalt, Thomas Wendl, Jan-Frederil Schlender, Michael Block, Thomas Eissing, Donato Teutonic -- 16 Exploiting nanocarriers for combination cancer therapy, Yi Wen Kong, Erik C. Dreaden, Paula T. Hammond and Michael B. Yaffe -- 17 Commercialization of nanotechnology for medical applications, David W. Hobson -- Index.
520 $a A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new “drugs” will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently “nanomaterials” have been said to “show promise” but none of these promises have so far been “reduced” to human clinical practice. The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies). Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies. Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug–carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile.
650 0 $a Medicine. $3 644133
650 0 $a Nanotechnology. $3 557660
650 1 4 $a Biomedicine, general. $3 1253757
700 1 $a Prokop, Aleš. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1262632
700 1 $a Weissig, Volkmar. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1115267
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319435237
776 0 8 $i Printed edition: $z 9783319435244
776 0 8 $i Printed edition: $z 9783319828466
830 0 $a Fundamental Biomedical Technologies, $x 1559-7083 $3 1272801
856 4 0 $u https://doi.org/10.1007/978-3-319-43525-1
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)